Review
Copyright ©The Author(s) 2016.
World J Clin Oncol. Oct 10, 2016; 7(5): 340-351
Published online Oct 10, 2016. doi: 10.5306/wjco.v7.i5.340
Figure 2
Figure 2 Possible resistance pathways to epidermal growth factor receptor blockade; gain of mutations in KRAS, BRAF, and PIK3CA and upregulation of other receptor tyrosine kinases. EGFR: Epidermal growth factor receptor; mTOR: Mechanistic target of rapamycin; PI3KCA: Phosphotidylinositol-3-kinase.